About CollaGenex Pharmaceuticals
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on the development and commercialization of proprietary, innovative medical therapies for the dermatology market. In July 2006, CollaGenex launched Oracea(R), the first FDA-approved systemic product for the treatment of rosacea. Collagenex's professional dermatology sales team also markets Alcortin(R) (1% iodoquinol and 2% hydrocortisone), a prescription antifungal steroid combination for topical use, and Novacort(R) (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription steroid and anesthetic for topical use. CollaGenex recently completed a Phase II clinical trial to evaluate COL-118, a topical compound based on SansRosa(R) technology for the treatment of redness associated with rosacea and other skin disorders. CollaGenex recently acquired the rights to develop and commercialize Becocalcidiol, a patented vitamin D analog currently in Phase II clinical trials for the topical treatment of mild to moderate psoriasis.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Advertisement
